From: Long-term outcomes after severe acute kidney injury in critically ill patients: the SALTO study
AKIKI trial | Surviving patients 60 days after randomization | Surviving patients with Scr available beyond D90 after randomization | |||
---|---|---|---|---|---|
No of patients | N = 619 | All N = 316 | Early RRT strategy N = 161 | Delayed RRT strategy N = 155 | N = 175 |
Age—yr | 66 ± 13.8 | 62.3 ± 14.7 | 60.8 ± 14.7 | 64 ± 14.7 | 62 ± 13 |
Sex—no. (%) | |||||
Female | 212(34) | 110 (35) | 55 (34) | 55 (35) | 60(34) |
Male | 407(66) | 206 (65) | 106(66) | 100 (65) | 115 (66) |
Serum creatinine before ICU admission—mg/dlb | 0.96 ± 0.28 | 0.95 ± 0.27 | 0.94 ± 0.25 | 0.96 ± 0.29 | 0.92 ± 0.23 |
Coexisting conditions—no. (%) | |||||
Chronic kidney diseasec | 118 (19) | 50 (16) | 23(14) | 27(17) | 7(4) |
Hypertension | 328 (53) | 153(48) | 71(44) | 82(53) | 70 (40) |
Diabetes mellitus | 163 (26) | 77 (24) | 42(26) | 35(23) | 35(20) |
Congestive heart failure | 56 (9) | 17 (5) | 8 (5) | 9(6) | 3(2) |
SAPS III at Enrollmentd | 73.1 ± 14.3 | 70.4 ± 14.8 | 70.8 ± 15.12 | 70 ± 14.05 | 66 ± 11 |
SOFA score at enrollmente | 10.9 ± 3.2 | 10.3 ± 3 | 10.5 ± 3.11 | 10.16 ± 2.85 | 9.8 ± 2.6 |
Exposure to at least one nephrotoxic agent within two days before ICU—no./total no. (%)g | |||||
All | 389 (63) | 178 (56) | 93 (58) | 85 (55) | 92(53) |
Intravenous contrast | 137 (22) | 70 (22) | 34/93 (37) | 36/85 (42) | 35/92 (38) |
Aminoglycoside | 212(34) | 95 (30) | 52/93 (56) | 43/85 (51) | 30/92 (33) |
Vancomycin | 55 (9) | 27 (8) | 12/93 (13) | 15/85 (18) | 5/92 (5) |
Septic shockg | 413 (67) | 167 (53) | 80 (50) | 87 (56) | 43/92 (47) |